References
- Gundelach JH, Madhavan AA, Wettstein PJ, Bram RJ. The anticancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism. FASEB J 2013;27(2):782–92.
- Richardson DR, Sharpe PC, Lovejoy DB, Senaratne D, Kalinowski DS, Islam M, et al. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J Med Chem 2006;49(22):6510–21.
- Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 2006;103(40):14901–6.
- Yuan J, Lovejoy DB, Richardson DR. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 2004;104(5):1450–8.
- Lovejoy DB, Jansson PJ, Brunk UT, Wong J, Ponka P, Richardson DR. Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res 2011;71(17):5871–80.
- Liu W, Xing F, Iiizumi-Gairani M, Okuda H, Watabe M, Pai SK, et al. N-myc downstream regulated gene 1 modulates Wnt-beta-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol Med 2012;4(2):93–108.
- Yu Y, Suryo Rahmanto Y, Hawkins CL, Richardson DR. The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity. Mol Pharmacol 2011;79(6):921–31.
- Buzas EI, Gyorgy B, Pasztoi M, Jelinek I, Falus A, Gabius HJ. Carbohydrate recognition systems in autoimmunity. Autoimmunity 2006;39(8):691–704.
- Chew V, Toh HC, Abastado JP. Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol 2012; Epub 8 August 2012 PMID: 22927846.
- Figge MT. Optimization of immunoglobulin substitution therapy by a stochastic immune response model. PLoS One 2009;4(5):e5685.
- Bernhardt PV, Sharpe PC, Islam M, Lovejoy DB, Kalinowski DS, Richardson DR. Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity. J Med Chem 2009;52(2):407–15.
- Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 2005;57(4):547–83.
- Yu Y, Suryo Rahmanto Y, Richardson DR. Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. Br J Pharmacol 2011;165(1):148–66.
- Kovacevic Z, Chikhani S, Lovejoy DB, Richardson DR. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol Pharmacol 2011;80(4):598–609.
- Lovejoy DB, Sharp DM, Seebacher N, Obeidy P, Prichard T, Stefani C, et al. Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo. J Med Chem 2012;55(16):7230–44.